Literature DB >> 20404278

Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response.

Jean-Jacques Hoarau1, Marie-Christine Jaffar Bandjee, Pascale Krejbich Trotot, Trina Das, Ghislaine Li-Pat-Yuen, Bérengère Dassa, Mélanie Denizot, Elsa Guichard, Anne Ribera, Tawfiq Henni, Frank Tallet, Marie Pierre Moiton, Bernard Alex Gauzère, Sandrine Bruniquet, Zaïnoul Jaffar Bandjee, Philippe Morbidelli, Gérard Martigny, Michel Jolivet, Frederick Gay, Marc Grandadam, Hugues Tolou, Vincent Vieillard, Patrice Debré, Brigitte Autran, Philippe Gasque.   

Abstract

Alphaviruses, including Chikungunya virus (CHIKV), produce a transient illness in humans, but severe forms leading to chronic incapacitating arthralgia/arthritis have been reported by mechanisms largely ill-characterized. The pathogenesis of CHIKV was addressed in a prospective cohort study of 49 hospitalized patients from Reunion Island subsequently categorized into two distinct groups at 12 mo postinfection. Comprehensive analyses of the clinical and immunological parameters throughout the disease course were analyzed in either the "recovered" or the "chronic" groups to identify prognostic markers of arthritis-like pathology after CHIKV disease. We found that the chronic group consisted mainly of more elderly patients (>60 y) and with much higher viral loads (up to 10(10) viruses per milliliter of blood) during the acute phase. Remarkably, a rapid innate immune antiviral response was demonstrated by robust dendritic/NK/CD4/CD8 cell activation and accompanied by a rather weak Th1/Th2 cytokine response in both groups. Interestingly, the antiviral immune response witnessed by high levels of IFN-alpha mRNA in PBMCs and circulating IL-12 persisted for months only in the chronic group. CHIKV (RNA and proteins) was found in perivascular synovial macrophages in one chronic patient 18 mo postinfection surrounded by infiltrating NK and T cells (CD4(++) but rare cytotoxic CD8). Fibroblast hyperplasia, strong angiogenesis, tissue lesions given the high levels of matrix metalloproteinase 2, and acute cell death [high cleaved poly(ADP-ribose) polymerase staining] were observed in the injured synovial tissue. These observed cellular and molecular events may contribute to chronic arthralgia/arthritis targeted by methotrexate used empirically for effective treatment but with immunosuppressive function in a context of viral persistence.

Entities:  

Mesh:

Year:  2010        PMID: 20404278     DOI: 10.4049/jimmunol.0900255

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  230 in total

Review 1.  Management of chikungunya arthritis.

Authors:  J Kennedy Amaral Pereira; Robert T Schoen
Journal:  Clin Rheumatol       Date:  2017-08-03       Impact factor: 2.980

2.  Immunopathogenesis of alphaviruses.

Authors:  Victoria K Baxter; Mark T Heise
Journal:  Adv Virus Res       Date:  2020-07-08       Impact factor: 9.937

3.  Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.

Authors:  Haiyan Chu; Subash C Das; Jeremy F Fuchs; M Suresh; Scott C Weaver; Dan T Stinchcomb; Charalambos D Partidos; Jorge E Osorio
Journal:  Vaccine       Date:  2013-05-29       Impact factor: 3.641

4.  The growth of arthralgic Ross River virus is restricted in human monocytic cells.

Authors:  Pascale Krejbich-Trotot; Essia Belarbi; Miora Ralambondrainy; Chaker El-Kalamouni; Wildriss Viranaicken; Pierre Roques; Philippe Desprès; Gilles Gadea
Journal:  Virus Res       Date:  2016-09-13       Impact factor: 3.303

5.  How many patients with post-chikungunya chronic inflammatory rheumatism can we expect in the new endemic areas of Latin America?

Authors:  A J Rodriguez-Morales; J A Cardona-Ospina; W Villamil-Gómez; A E Paniz-Mondolfi
Journal:  Rheumatol Int       Date:  2015-06-05       Impact factor: 2.631

6.  A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

Authors:  Juan García-Arriaza; Victoria Cepeda; David Hallengärd; Carlos Óscar S Sorzano; Beate Mareike Kümmerer; Peter Liljeström; Mariano Esteban
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

7.  Chikungunya fever: focus on peripheral markers of pathogenesis.

Authors:  Pierre Roques; Gabriel Gras
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

8.  A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence.

Authors:  Thomas E Morrison; Lauren Oko; Stephanie A Montgomery; Alan C Whitmore; Alina R Lotstein; Bronwyn M Gunn; Susan A Elmore; Mark T Heise
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

9.  CD8+ T cells control Ross River virus infection in musculoskeletal tissues of infected mice.

Authors:  Kristina S Burrack; Stephanie A Montgomery; Dirk Homann; Thomas E Morrison
Journal:  J Immunol       Date:  2014-12-08       Impact factor: 5.422

10.  Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor.

Authors:  Angela Chow; Zhisheng Her; Edward K S Ong; Jin-miao Chen; Frederico Dimatatac; Dyan J C Kwek; Timothy Barkham; Henry Yang; Laurent Rénia; Yee-Sin Leo; Lisa F P Ng
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.